New Therapy for Retinoblastoma by Targeting Retinal Progenitor Cells

通过靶向视网膜祖细胞治疗视网膜母细胞瘤的新疗法

• 批准号: 22659311
• 负责人: UEMURA Akiyoshi
• 金额: $ 2.2万
• 依托单位: Kobe University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Challenging Exploratory Research
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22659311/
• 关键词: 網膜芽細胞腫; 網膜前駆細胞; ミュラーグリア細胞; Tlx; VEGFR2; VEGF受容体; MASH1

Retinoblastoma is caused by deregulated proliferation of retinal progenitor cells, which normally differentiate into all types of retinal neurons and Muller glia. Therefore, it is expected that molecular mechanisms which regulate differentiation and proliferation of retinal progenitor cells can be novel targets to treat retinoblastoma. In this research program, we demonstrated that the nuclear receptor Tlx and the receptor tyrosine kinase VEGFR2 are co-expressed in retinal progenitor cells, and disruptions of these genes similarly resulted in abnormal development and impaired homeostasis of mouse retinal tissues.

视网膜母细胞瘤是由视网膜祖细胞的增殖失调引起的，视网膜祖细胞通常分化成所有类型的视网膜神经元和Muller胶质细胞。因此，可以预期调节视网膜祖细胞分化和增殖的分子机制可以成为治疗视网膜母细胞瘤的新靶点。在这项研究计划中，我们证明了核受体Tlx和受体酪氨酸激酶VEGFR2在视网膜祖细胞中共表达，这些基因的破坏同样会导致小鼠视网膜组织的发育异常和稳态受损。

项目成果

TLX activates MASH1 for induction of neuronal lineage commitment of adult hippocampal neuroprogenitors

• DOI: 10.1016/j.mcn.2010.06.003
• 发表时间: 2010-10-01
• 期刊: MOLECULAR AND CELLULAR NEUROSCIENCE
• 影响因子: 3.5
• 作者: Elmi, Muna;Matsumoto, Yoshiki;Funa, Keiko
• 通讯作者: Funa, Keiko